These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38116854)

  • 1. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.
    Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W
    Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
    Steinebach C; Bricelj A; Murgai A; Sosič I; Bischof L; Ng YLD; Heim C; Maiwald S; Proj M; Voget R; Feller F; Košmrlj J; Sapozhnikova V; Schmidt A; Zuleeg MR; Lemnitzer P; Mertins P; Hansen FK; Gütschow M; Krönke J; Hartmann MD
    J Med Chem; 2023 Nov; 66(21):14513-14543. PubMed ID: 37902300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation.
    Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W
    J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cereblon in hematologic malignancies.
    Fuchs O
    Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Degron Blocking Strategy Towards Improved CRL4
    Bouguenina H; Scarpino A; O'Hanlon JA; Warne J; Wang HZ; Wah Hak LC; Sadok A; McAndrew PC; Stubbs M; Pierrat OA; Hahner T; Cabry MP; Le Bihan YV; Mitsopoulos C; Sialana FJ; Roumeliotis TI; Burke R; van Montfort RLM; Choudhari J; Chopra R; Caldwell JJ; Collins I
    Chembiochem; 2023 Dec; 24(23):e202300351. PubMed ID: 37418539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cereblon as a primary target of IMiDs].
    Ito T; Handa H
    Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
    Dann GP; Liu H; Nowak RP; Jones LH
    Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase-Based Partial PROTAC Library.
    Almodóvar-Rivera CM; Zhang Z; Li J; Xie H; Zhao Y; Guo L; Mannhardt MG; Tang W
    Chembiochem; 2023 Oct; 24(20):e202300482. PubMed ID: 37418320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligands for cereblon: 2017-2021 patent overview.
    Kazantsev A; Krasavin M
    Expert Opin Ther Pat; 2022 Feb; 32(2):171-190. PubMed ID: 34704527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.
    Min J; Mayasundari A; Keramatnia F; Jonchere B; Yang SW; Jarusiewicz J; Actis M; Das S; Young B; Slavish J; Yang L; Li Y; Fu X; Garrett SH; Yun MK; Li Z; Nithianantham S; Chai S; Chen T; Shelat A; Lee RE; Nishiguchi G; White SW; Roussel MF; Potts PR; Fischer M; Rankovic Z
    Angew Chem Int Ed Engl; 2021 Dec; 60(51):26663-26670. PubMed ID: 34614283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
    Zhou L; Xu G
    J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
    Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
    Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent topics in IMiDs and cereblon].
    Ito T; Handa H
    Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.